FY2025 Earnings Estimate for TWST Issued By Leerink Partnrs

Twist Bioscience Co. (NASDAQ:TWST) – Investment analysts at Leerink Partnrs cut their FY2025 earnings estimates for Twist Bioscience in a research report issued on Monday, May 5th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($2.24) per share for the year, down from their prior forecast of ($2.23). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.12) per share. Leerink Partnrs also issued estimates for Twist Bioscience’s Q4 2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.68) EPS.

TWST has been the subject of several other reports. Robert W. Baird decreased their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. JPMorgan Chase & Co. reduced their price objective on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday. Barclays dropped their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Finally, Guggenheim reaffirmed a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.40.

Twist Bioscience Price Performance

NASDAQ TWST opened at $30.82 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. The stock has a 50-day moving average of $38.63 and a 200 day moving average of $43.65. Twist Bioscience has a one year low of $30.72 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million for the quarter, compared to analysts’ expectations of $92.00 million.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its stake in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares during the period. Avanza Fonder AB purchased a new position in shares of Twist Bioscience during the 4th quarter worth about $1,059,000. Principal Financial Group Inc. grew its holdings in Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after purchasing an additional 82,953 shares during the last quarter. Vanguard Group Inc. raised its position in Twist Bioscience by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after purchasing an additional 189,791 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in Twist Bioscience by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company’s stock worth $1,761,000 after purchasing an additional 9,722 shares during the last quarter.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,402 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $98,265.82. Following the sale, the chief executive officer now owns 662,692 shares in the company, valued at approximately $27,110,729.72. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Paula Green sold 918 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now owns 130,912 shares of the company’s stock, valued at $5,355,609.92. This trade represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,991 shares of company stock valued at $742,654. Insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.